WO2003084553A1 - Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis - Google Patents

Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis Download PDF

Info

Publication number
WO2003084553A1
WO2003084553A1 PCT/EP2003/003329 EP0303329W WO03084553A1 WO 2003084553 A1 WO2003084553 A1 WO 2003084553A1 EP 0303329 W EP0303329 W EP 0303329W WO 03084553 A1 WO03084553 A1 WO 03084553A1
Authority
WO
WIPO (PCT)
Prior art keywords
proanthocyanidins
pharmaceutical compositions
dermatitis
treatment
acid
Prior art date
Application number
PCT/EP2003/003329
Other languages
French (fr)
Inventor
Marco Mastrodonato
Roberto Ciattini
Original Assignee
Sinclair Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2481770A priority Critical patent/CA2481770C/en
Priority to AU2003226754A priority patent/AU2003226754B2/en
Priority to JP2003581793A priority patent/JP4861606B2/en
Priority to DE60313597T priority patent/DE60313597T2/en
Priority to GEAP8438A priority patent/GEP20074176B/en
Priority to MXPA04009755A priority patent/MXPA04009755A/en
Priority to KR1020047015962A priority patent/KR101065645B1/en
Priority to EP03745775A priority patent/EP1494692B1/en
Priority to UA20040907928A priority patent/UA81408C2/en
Priority to SI200330829T priority patent/SI1494692T1/en
Priority to BRPI0309061-2A priority patent/BRPI0309061B1/en
Priority to NZ535813A priority patent/NZ535813A/en
Application filed by Sinclair Pharmaceuticals Limited filed Critical Sinclair Pharmaceuticals Limited
Priority to BR0309061-2A priority patent/BR0309061A/en
Priority to DK03745775T priority patent/DK1494692T3/en
Priority to CN038078589A priority patent/CN1646151B/en
Publication of WO2003084553A1 publication Critical patent/WO2003084553A1/en
Priority to HRP20040917AA priority patent/HRP20040917B1/en
Priority to IL164434A priority patent/IL164434A/en
Priority to NO20044259A priority patent/NO332753B1/en
Priority to US10/963,848 priority patent/US7262180B2/en
Priority to HK05107779.7A priority patent/HK1075617A1/en
Priority to US11/358,747 priority patent/US20060247183A1/en
Priority to CY20071100718T priority patent/CY1106628T1/en
Priority to US11/841,564 priority patent/US20080015155A1/en
Priority to US12/013,244 priority patent/US20080114057A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to pharmaceutical compositions for the topical administration comprising as active ingredients proanthocyanidins, glycyrrhetinic acid and telmesteine, in admixture with a suitable carrier.
  • topical pharmaceutical compositions of the present invention are useful for the treatment of inflammatory conditions of the skin, such as atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, psoriasis, xerosis and atopia as well as of mucosae and eye inflammatory conditions.
  • Dermatites are superficial skin inflammations, characterized by vesicles, erythema, edema, oozing, scaling or crusting lesions and intense itching.
  • the treatment consists in removing the offending agent, which however cannot in many cases be identified or removed.
  • Treatment is therefore based on corticosteroids, which have however well known side-effects: they reduce the immune defenses, which can induce infections, mainly by fungi or Candida; suspension of the treatment should be gradual; they cannot be used during the acute oozing phase; a rebound effect may appear on stopping treatment. Furthermore, corticosteroids should not be used for prolonged treatments, particularly in children, since they can give rise to systemic effects.
  • EP 0 694 305 discloses topical compositions of proanthocyanidins combined with coumarins (esculoside and the like) for the treatment of peripheral vasculopathies, such as bedsores, scars, couperose, varices and the like.
  • US 5,470,874 describes a combination of proanthocyanidins and vitamin C for the topical use, as sunscreen, for stimulating collagen synthesis and for restoring damaged collagen.
  • JP 6,336,421 relates to topical formulations of proanthocyanidins combined with anti-inflammatories, among which glycyrrhetinic acid and derivatives are cited, for the cosmetic use and against sunburns.
  • proanthocyanidins in the treatment of pathologies such as chronic dermatitis, seborrheic dermatitis and allergic dermatis has not been described.
  • Proanthocyanidins are widely diffused in a number of vegetable species. They are vegetable extracts containing bioflavonoids, with well-defined chemical profile, consisting for about 15% of dimers, about 20% of trimers and tetramers, and of small amounts of catechin and epicatechin. Proanthocyanidins exert both skin protecting action from the aggression by free radicals and restoration action of the damages to the skin structure through stimulation of collagen production. They also contain essential fatty acids similar to those of the skin hydrolipidic barrier, which contribute to keep said barrier intact.
  • proanthocyanidins reduce the concentration of enzymes such as elastase, collagenase, hyaluronidase and beta-glucuronidase, which are responsible for the destruction of elastin, collagen and hyaluronic acid proteins. Therefore, proanthocyanidins are widely used in the pharmaceutical and cosmetic industries, thanks to their restoring, regenerating, nutrient and restructurant actions, which restores the skin elasticity and tonicity. According to the present invention, the proanthocyanidins extracted from grape seeds and skin of Vitis vinifera are particularly preferred. Most preferred are the complexes of proanthocyanidins from Vitis vinifera with phospholipids, prepared according to the process disclosed in US 4,963,527.
  • 18- ⁇ -Glycyrrhetinic acid extracted from the roots of Glycyrrhiza glabra, is known to have antiinflammatory properties on the skin, in particular in case of burns and redness.
  • Telmesteine (N-carbethoxy-4-thiazolidinecarboxylic acid) exerts antiradicalic and protective action against the oxidizing agents responsible for skin damages, as well as inhibiting elastase and collagenase actions.
  • the topical pharmaceutical compositions of the present invention will contain the active ingredients in admixture with a suitable carrier, preferably a carrier rich in polyunsaturated fatty acids.
  • suitable carriers comprise squalene, fatty acids, fatty acids esters, vegetable oils, natural or synthetic triglycerids. More preferably, suitable carriers comprise squalene, karite butter, octyl palmitate and oenothera oil.
  • karite butter also known as shea butter
  • shea butter is a fat consisting of a mixture of saturated and unsaturated fats, extracted from the seeds of Butirospermum parkii, a tree from northern Africa, which is used in cosmetics thanks to its protective and softening actions, which make it particularly useful for sensitive skins as well as for skins which easily redden.
  • Oenothera oil also known as evening primrose oil
  • Oenothera biennis is rich in essential polyunsaturated fatty acids, in particular ⁇ -linolenic acid, indispensable for regenerating the skin and all cellular tissues.
  • the pharmaceutical compositions of the invention will further contain compounds with antioxidizing activity, such as tocopherols and ascorbic acid or esters thereof, preferably tocopherol acetate and ascorbyl palmitate or tetrapalmitate, to further increase the protective effect on cell membranes and to slow down the oxidation of polyunsaturated fatty acids.
  • compounds with antioxidizing activity such as tocopherols and ascorbic acid or esters thereof, preferably tocopherol acetate and ascorbyl palmitate or tetrapalmitate, to further increase the protective effect on cell membranes and to slow down the oxidation of polyunsaturated fatty acids.
  • compositions of the present invention may further contain other active ingredients, with complementary or anyway useful actions in the treatment of dermatosis .
  • a further preferred embodiment relates to the pharmaceutical compositions of the invention also containing salicylic acid, for the
  • a further preferred embodiment relates to the pharmaceutical compositions of the invention also containing hyaluronic acid, for the treatment of radiation dermatitis.
  • a further preferred embodiment relates to the pharmaceutical compositions of the invention also containing alpha-bisabolol and allantoin.
  • a further preferred embodiment relates to the pharmaceutical compositions of the invention also containing zinc pidolate.
  • topical pharmaceutical compositions of the present invention can be in the form of cream, gel, lotion, suspension, spray, ointment, foam.
  • the topical pharmaceutical compositions of the present invention will contain the active ingredients in the following concentrations (w/w): a) proanthocyanidins in the form of complexes with phospholipids: 0.01% to 1%; b) glycyrrhetinic acid: 0.1 to 5%, preferably 1 to 2%; c) telmesteine: 0.01% to 1%; and - carriers (squalene, karite butter, octyl palmitate and oenothera oil):
  • antioxidants tocopherol acetate 0.5-5%; ascorbyl palmitate 0.01- 0.1%
  • the daily dosage will be determined by the physician; by way of example, it will consist of one or more daily applications even for protracted times.
  • Example 1 Some examples of formulations according to the present invention are shown hereinafter.
  • Example 1 Some examples of formulations according to the present invention are shown hereinafter.
  • compositions of the present invention showed very good tolerability. They do not contain allergenic substances, derivatives from animal sources (such as lanolin, beeswax, animal fat), preservatives (such as parabens, isothiazolones, phenol derivatives, and the like) which are often responsible for allergic contact dermatitis.
  • animal sources such as lanolin, beeswax, animal fat
  • preservatives such as parabens, isothiazolones, phenol derivatives, and the like
  • compositions of the present invention are useful for the treatment of already existing skin allergic reactions, for the prevention of recurrent forms, and as adjuvants in the treatment of chronic diseases such as atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, xerosis and atopia.
  • compositions of the present invention are useful in the treatment of conditions such as irritative and eczematous dermatitis, as moisturizers and lenitive agents for sensitive, delicate skin; in allergic irritations due to medicaments, detergents, solvents; in erythema due to excessive exposure to sun radiaitons; in case of insect stings, redness of various origin, post-shaving irritations, slight burns, skin hyper-reactivity; as normalizers after esthetic treatments, such as peeling with acid glycolic or laser-therapy.
  • the excellent tolerability of the compositions of the present invention makes them also suitable in pediatrics.
  • the present invention also relates to the use of proanthocyanidins for the preparation of a topical medicament for the treatment of skin inflammations, in particular atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, xerosis, psoriasis and atopia; and of mucosae inflammatory conditions, in particular of vaginal, rectal, eye gingival and buccal mucosae.
  • skin inflammations in particular atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, xerosis, psoriasis and atopia
  • mucosae inflammatory conditions in particular of vaginal, rectal, eye gingival and buccal mucosae.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Pharmaceutical compositions for the topical administration, comprising as active ingredients proanthocyanidins alone or combined with glycyrrhetinic acid, telmesteine, alpha-bisabolol or other components having complementary activity, in admixture with a suitable carrier, useful for the treatment of avariety of pathologies such as atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, psoriasis, xerosis and atopia as well as for the treatment of mucosae inflammatory conditions.

Description

TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING PROANTHOCYANIDINS FOR THE TREATMENT OF DERMATITIS
The present invention relates to pharmaceutical compositions for the topical administration comprising as active ingredients proanthocyanidins, glycyrrhetinic acid and telmesteine, in admixture with a suitable carrier.
The topical pharmaceutical compositions of the present invention are useful for the treatment of inflammatory conditions of the skin, such as atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, psoriasis, xerosis and atopia as well as of mucosae and eye inflammatory conditions.
Dermatites are superficial skin inflammations, characterized by vesicles, erythema, edema, oozing, scaling or crusting lesions and intense itching. Various types of dermatitis exist: contact dermatitis, which can be caused by irritants with which the skin is in contact or by non-irritating substances to which the subject is allergic; atopic dermatitis, a chronic disease characterized by strong itching; seborrheic dermatitis, a scaling disease which mainly affect the face and scalp. In principle, the treatment consists in removing the offending agent, which however cannot in many cases be identified or removed. Treatment is therefore based on corticosteroids, which have however well known side-effects: they reduce the immune defenses, which can induce infections, mainly by fungi or Candida; suspension of the treatment should be gradual; they cannot be used during the acute oozing phase; a rebound effect may appear on stopping treatment. Furthermore, corticosteroids should not be used for prolonged treatments, particularly in children, since they can give rise to systemic effects.
In the case of seborrheic dermatitis, alternative treatments, based on hydrogenated vegetable oils or hydrophilic petrolatum, or medicated shampoos (based on zinc-pirithione, selenium sulfϊde, sulfur and the like) in are not resolutive.
In case of the mucosae inflammatory conditions, in particular of mouth, gingival, rectal, vaginal and eye mucosae, a number of topical treatments are available, including the use of steroidal or non-steroidal antiinfiammatory agents, with the problems and side effects characteristics for these medicaments.
Different uses of proanthocyanidins have been described in the pharmaceutical and cosmetic fields. EP 0 694 305 discloses topical compositions of proanthocyanidins combined with coumarins (esculoside and the like) for the treatment of peripheral vasculopathies, such as bedsores, scars, couperose, varices and the like. US 5,470,874 describes a combination of proanthocyanidins and vitamin C for the topical use, as sunscreen, for stimulating collagen synthesis and for restoring damaged collagen. Finally, JP 6,336,421 relates to topical formulations of proanthocyanidins combined with anti-inflammatories, among which glycyrrhetinic acid and derivatives are cited, for the cosmetic use and against sunburns. However, to date the use of proanthocyanidins in the treatment of pathologies such as chronic dermatitis, seborrheic dermatitis and allergic dermatis has not been described.
Proanthocyanidins are widely diffused in a number of vegetable species. They are vegetable extracts containing bioflavonoids, with well-defined chemical profile, consisting for about 15% of dimers, about 20% of trimers and tetramers, and of small amounts of catechin and epicatechin. Proanthocyanidins exert both skin protecting action from the aggression by free radicals and restoration action of the damages to the skin structure through stimulation of collagen production. They also contain essential fatty acids similar to those of the skin hydrolipidic barrier, which contribute to keep said barrier intact. Finally, proanthocyanidins reduce the concentration of enzymes such as elastase, collagenase, hyaluronidase and beta-glucuronidase, which are responsible for the destruction of elastin, collagen and hyaluronic acid proteins. Therefore, proanthocyanidins are widely used in the pharmaceutical and cosmetic industries, thanks to their restoring, regenerating, nutrient and restructurant actions, which restores the skin elasticity and tonicity. According to the present invention, the proanthocyanidins extracted from grape seeds and skin of Vitis vinifera are particularly preferred. Most preferred are the complexes of proanthocyanidins from Vitis vinifera with phospholipids, prepared according to the process disclosed in US 4,963,527.
18-β-Glycyrrhetinic acid, extracted from the roots of Glycyrrhiza glabra, is known to have antiinflammatory properties on the skin, in particular in case of burns and redness.
Telmesteine (N-carbethoxy-4-thiazolidinecarboxylic acid) exerts antiradicalic and protective action against the oxidizing agents responsible for skin damages, as well as inhibiting elastase and collagenase actions. The topical pharmaceutical compositions of the present invention will contain the active ingredients in admixture with a suitable carrier, preferably a carrier rich in polyunsaturated fatty acids. According to the invention, suitable carriers comprise squalene, fatty acids, fatty acids esters, vegetable oils, natural or synthetic triglycerids. More preferably, suitable carriers comprise squalene, karite butter, octyl palmitate and oenothera oil.
In particular, karite butter (also known as shea butter) is a fat consisting of a mixture of saturated and unsaturated fats, extracted from the seeds of Butirospermum parkii, a tree from northern Africa, which is used in cosmetics thanks to its protective and softening actions, which make it particularly useful for sensitive skins as well as for skins which easily redden.
Oenothera oil (also known as evening primrose oil), extracted from the plant Oenothera biennis, is rich in essential polyunsaturated fatty acids, in particular γ-linolenic acid, indispensable for regenerating the skin and all cellular tissues.
According to a preferred embodiment, the pharmaceutical compositions of the invention will further contain compounds with antioxidizing activity, such as tocopherols and ascorbic acid or esters thereof, preferably tocopherol acetate and ascorbyl palmitate or tetrapalmitate, to further increase the protective effect on cell membranes and to slow down the oxidation of polyunsaturated fatty acids.
The compositions of the present invention may further contain other active ingredients, with complementary or anyway useful actions in the treatment of dermatosis .
Examples of said active ingredients are: salicylic acid, which exerts a keratolytic action useful for the treatment of seborrheic dermatitis; hyaluronic acid, which is useful for the treatment of radiation dermatitis due to its hydrating and healing action; alpha-bisabolol, one of the active principles present in chamomile essential oil (Matricaria flos), which has lenitive and anti-redness action; zinc pidolate, which exerts slightly astringent, emollient and lenitive actions, blocks and prevents the formation of free radicals thanks to its competitive action towards iron ions, and is active in the enzymatic processes of skin metabolism; allantoin which has astringent, slightly keratolytic and healing actions; moisturizers or wetting agents; piroctone olamine (octopirox), a known agent with antiseborrhoic activity. Therefore, a further preferred embodiment relates to the pharmaceutical compositions of the invention also containing salicylic acid, for the treatment of seborrheic dermatitis.
A further preferred embodiment relates to the pharmaceutical compositions of the invention also containing hyaluronic acid, for the treatment of radiation dermatitis.
A further preferred embodiment relates to the pharmaceutical compositions of the invention also containing alpha-bisabolol and allantoin. A further preferred embodiment relates to the pharmaceutical compositions of the invention also containing zinc pidolate.
The topical pharmaceutical compositions of the present invention can be in the form of cream, gel, lotion, suspension, spray, ointment, foam.
The topical pharmaceutical compositions of the present invention will contain the active ingredients in the following concentrations (w/w): a) proanthocyanidins in the form of complexes with phospholipids: 0.01% to 1%; b) glycyrrhetinic acid: 0.1 to 5%, preferably 1 to 2%; c) telmesteine: 0.01% to 1%; and - carriers (squalene, karite butter, octyl palmitate and oenothera oil):
10-50%;
- antioxidants (tocopherol acetate 0.5-5%; ascorbyl palmitate 0.01- 0.1%);
- salicylic acid 0.1-5%; - hyaluronic acid 0.1-10%;
- alfa-bisabolol 0.1-3%;
- zinc pidolate 0.01-1%;
- allantoin 0.1-2%.
The daily dosage will be determined by the physician; by way of example, it will consist of one or more daily applications even for protracted times.
Some examples of formulations according to the present invention are shown hereinafter. Example 1
CREAM
Figure imgf000007_0001
Example 2
CREAM
Figure imgf000008_0001
Example 3
CREAM
Figure imgf000009_0001
Example 4
CREAM
Figure imgf000010_0001
Example 5
CREAM
Figure imgf000011_0001
Example 6
CREAM
Figure imgf000012_0001
Example 7
CREAM
Figure imgf000013_0001
Example 8
CREAM
Figure imgf000014_0001
The compositions of the present invention showed very good tolerability. They do not contain allergenic substances, derivatives from animal sources (such as lanolin, beeswax, animal fat), preservatives (such as parabens, isothiazolones, phenol derivatives, and the like) which are often responsible for allergic contact dermatitis.
Therefore, thanks to the above mentioned characteristics, the compositions of the present invention are useful for the treatment of already existing skin allergic reactions, for the prevention of recurrent forms, and as adjuvants in the treatment of chronic diseases such as atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, xerosis and atopia.
More particularly, the compositions of the present invention are useful in the treatment of conditions such as irritative and eczematous dermatitis, as moisturizers and lenitive agents for sensitive, delicate skin; in allergic irritations due to medicaments, detergents, solvents; in erythema due to excessive exposure to sun radiaitons; in case of insect stings, redness of various origin, post-shaving irritations, slight burns, skin hyper-reactivity; as normalizers after esthetic treatments, such as peeling with acid glycolic or laser-therapy. The excellent tolerability of the compositions of the present invention makes them also suitable in pediatrics.
The present invention also relates to the use of proanthocyanidins for the preparation of a topical medicament for the treatment of skin inflammations, in particular atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, xerosis, psoriasis and atopia; and of mucosae inflammatory conditions, in particular of vaginal, rectal, eye gingival and buccal mucosae.

Claims

1. The use of proanthocyanidins for the preparation of a topical medicament for the treatment of inflammatory conditions of the skin and mucosae.
2. The use as claimed in claim 1 for the treatment of atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, xerosis, psoriasis and atopia.
3. The use as claimed in claim 1 for the treatment of inflammatory conditions of the vaginal, rectal, buccal and eye mucosae.
4. The use as claimed in any one of claims 1-3, in which proanthocyanidins are in the form of complexes with phospholipids.
5. The use as claimed in any one of claims 1-4, in which proanthocyanidins are in combination with glycyrrhetinic acid.
6. The use as claimed in any one of claims 1-5, in which proanthocyanidins are further in combination with telmesteine.
7. The use as claimed in any one of claims 1-6, in which proanthocyanidins are further in combination with alpha-bisabolol.
8. The use as claimed in any one of claims 1-7, in which proanthocyanidins are further in combination with piroctone olamine.
9. The use as claimed in any one of claims 1-8, in which proanthocyanidins are further in combination with wetting agents and moisturizers.
10. Pharmaceutical compositions for the topical administration, comprising as active ingredients proanthocyanidins, glycyrrhetinic acid and telmesteine in admixture with a suitable carrier.
1 1. Pharmaceutical compositions as claimed in claim 10, in the form of cream, gel, lotion, suspension, spray, ointment, foam.
12. Pharmaceutical compositions as claimed in claim 10 or 11, in which the carrier comprises squalene, fatty acids, fatty acids esters, vegetable oils, natural or synthetic triglycerids.
13. Pharmaceutical compositions as claimed in claim 12, in which the carrier comprises squalene, karite butter, octyl palmitate and oenothera oil.
14. Pharmaceutical compositions as claimed in any one of claims 10-13, further comprising tocopherols, ascorbic acid or esters thereof.
15. Pharmaceutical compositions as claimed in claim 14, comprising tocopherol acetate and ascorbyl palmitate or tetrapalmitate.
16. Pharmaceutical compositions as claimed in any one of claims 10-15, comprising salicylic acid.
17. Pharmaceutical compositions as claimed in any one of claims 10-16, comprising hyaluronic acid.
18. Pharmaceutical compositions as claimed in any one of claims 10-17, further comprising at least one compound selected from alpha-bisabolol, zinc pidolate, allantoin, piroctone olamine.
19. Pharmaceutical compositions as claimed in any one of claims 10-18, in which the active ingredients are present in the following concentrations: a) proanthocyanidins in the form of complexes with phospholipids: 0.01% to 1%; b) glycyrrhetinic acid: 0.1 to 5%; c) telmesteine: 0.01% to 1%.
20. Compositions as claimed in claim 19 in which glycyrrhetinic acid is present in concentrations ranging from 1 to 2%.
21. A method of treatment of patients affected with skin and mucosae inflammatory conditions, which comprises the topical administration of an effective amount of proanthocyanidins.
22. A method as claimed in claim 21 for the treatment of atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, xerosis, psoriasis and atopia.
23. A method as claimed in claim 21 or 22 which further comprises the topical administration of telmesteine.
24. A method as claimed in claim 21, 22 or 23 which further comprises the topical administration of glycyrrhetinic acid.
25. A method as claimed in any one of the claims 21-24 which further comprises the topical administration of one or more agents selected from salicylic acid, allantoin, hyaluronic acid, zinc pidolate, alpha-bisabolol, piroctone olamine.
PCT/EP2003/003329 2002-04-09 2003-03-31 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis WO2003084553A1 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
BR0309061-2A BR0309061A (en) 2002-04-09 2003-03-31 Topical pharmaceutical compositions comprising pro-anthocyanidins for treating dermatitis
AU2003226754A AU2003226754B2 (en) 2002-04-09 2003-03-31 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
DK03745775T DK1494692T3 (en) 2002-04-09 2003-03-31 Topical pharmaceutical compositions comprising proanthocyanidins, glycyrrhetinic acid and telmestein for the treatment of dermatitis
GEAP8438A GEP20074176B (en) 2002-04-09 2003-03-31 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
MXPA04009755A MXPA04009755A (en) 2002-04-09 2003-03-31 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis.
KR1020047015962A KR101065645B1 (en) 2002-04-09 2003-03-31 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
EP03745775A EP1494692B1 (en) 2002-04-09 2003-03-31 Topical pharmaceutical compositions comprising proanthocyanidins, glycyrrhetinic acid and telmesteine for the treatment of dermatitis
UA20040907928A UA81408C2 (en) 2002-04-09 2003-03-31 Topical pharmaceutical composition and use thereof for the preparation of medicament for treatment of dermatitis and mucosae inflammatory conditions
SI200330829T SI1494692T1 (en) 2002-04-09 2003-03-31 Topical pharmaceutical compositions comprising proanthocyanidins, glycyrrhetinic acid and telmesteine for the treatment of dermatitis
BRPI0309061-2A BRPI0309061B1 (en) 2002-04-09 2003-03-31 TOPICAL PHARMACEUTICAL COMPOSITION UNDERSTANDING PRO-ANTOCYANIDINES, GLYCYRETHINIC ACID AND TELMESTEIN FOR TREATMENT OF INFLAMMATORY SKIN AND MUCOSUS CONDITIONS AND USE OF THE SAME
NZ535813A NZ535813A (en) 2002-04-09 2003-03-31 Topical pharmaceutical compositions comprising proanthocyanidins glycyrrhetinic acid and telmesteine for the treatment of dermatitis
CA2481770A CA2481770C (en) 2002-04-09 2003-03-31 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
JP2003581793A JP4861606B2 (en) 2002-04-09 2003-03-31 Topical pharmaceutical composition comprising proanthocyanidins for treating dermatitis
DE60313597T DE60313597T2 (en) 2002-04-09 2003-03-31 TOPICAL PHARMACEUTICAL COMPOSITIONS WITH PROANTHOCYANIDINES, GLYCYRRHETINIC ACID AND TELEMINE TESTS FOR THE TREATMENT OF DERMATITIS
CN038078589A CN1646151B (en) 2002-04-09 2003-03-31 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
HRP20040917AA HRP20040917B1 (en) 2002-04-09 2004-10-05 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
IL164434A IL164434A (en) 2002-04-09 2004-10-05 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
NO20044259A NO332753B1 (en) 2002-04-09 2004-10-07 Topical pharmaceutical compositions containing proanthocyanidins for the treatment of dermatitis.
US10/963,848 US7262180B2 (en) 2002-04-09 2004-10-12 Compositions and methods for the treatment of inflammatory conditions of mucosae, skin and the eye
HK05107779.7A HK1075617A1 (en) 2002-04-09 2005-09-05 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
US11/358,747 US20060247183A1 (en) 2002-04-09 2006-02-21 Compositions and methods for the treatment of inflammatory conditions of mucosae, skin and the eye
CY20071100718T CY1106628T1 (en) 2002-04-09 2007-05-29 TOPICAL PHARMACEUTICAL COMPOSITIONS INCLUDING PROANTHOCYANIDINS, GLYCYRACHITINIC ACID AND TELMESTEIN FOR THE TREATMENT OF DERMATITIS
US11/841,564 US20080015155A1 (en) 2002-04-09 2007-08-20 Compositions and Methods for the Treatment of Inflammatory Conditions of the Mucosae, Skin and the Eye
US12/013,244 US20080114057A1 (en) 2002-04-09 2008-01-11 Compositions and methods for the treatment of inflammatory conditions of the mucosae, skin and the eye

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002MI000756A ITMI20020756A1 (en) 2002-04-09 2002-04-09 TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DERMATITIS
ITMI2002A000756 2002-04-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/963,848 Continuation-In-Part US7262180B2 (en) 2002-04-09 2004-10-12 Compositions and methods for the treatment of inflammatory conditions of mucosae, skin and the eye

Publications (1)

Publication Number Publication Date
WO2003084553A1 true WO2003084553A1 (en) 2003-10-16

Family

ID=11449673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/003329 WO2003084553A1 (en) 2002-04-09 2003-03-31 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis

Country Status (31)

Country Link
US (4) US7262180B2 (en)
EP (1) EP1494692B1 (en)
JP (1) JP4861606B2 (en)
KR (1) KR101065645B1 (en)
CN (1) CN1646151B (en)
AR (1) AR039269A1 (en)
AT (1) ATE361084T1 (en)
AU (1) AU2003226754B2 (en)
BR (2) BRPI0309061B1 (en)
CA (1) CA2481770C (en)
CY (1) CY1106628T1 (en)
DE (1) DE60313597T2 (en)
DK (1) DK1494692T3 (en)
ES (1) ES2285158T3 (en)
GE (1) GEP20074176B (en)
HK (1) HK1075617A1 (en)
HR (1) HRP20040917B1 (en)
IL (1) IL164434A (en)
IT (1) ITMI20020756A1 (en)
JO (1) JO2448B1 (en)
MX (1) MXPA04009755A (en)
MY (1) MY137060A (en)
NO (1) NO332753B1 (en)
NZ (1) NZ535813A (en)
PL (1) PL204953B1 (en)
PT (1) PT1494692E (en)
RU (1) RU2320362C2 (en)
TW (1) TWI345979B (en)
UA (1) UA81408C2 (en)
WO (1) WO2003084553A1 (en)
ZA (1) ZA200408100B (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103321A2 (en) * 2003-05-16 2004-12-02 Johnson & Johnson Consumer Companies, Inc. Topical treatment of ingrown hairs
WO2004103353A2 (en) * 2003-05-16 2004-12-02 Johnson & Johnson Consumer Companies, Inc. Topical treatment of sebum related skin conditions
WO2005037275A1 (en) * 2003-10-09 2005-04-28 Sinclair Pharmaceuticals Limited Topical compositions comprising telmesteine for treating dermatological disorders
FR2871060A1 (en) * 2004-06-08 2005-12-09 Ajinomoto Kk SUPPRESSOR AGENT FOR INFLAMMATION AND METHOD USING THE SAME
JP2006022090A (en) * 2004-06-08 2006-01-26 Ajinomoto Co Inc Inflammation inhibitor composed of pyrrolidonecarboxylic acid zinc salt
WO2008054639A2 (en) * 2006-10-30 2008-05-08 Insite Vision Incorporated Use of a catechin or polyphenol to treat ocular diseases and infection
DE102007017851A1 (en) * 2007-04-16 2008-10-23 Schülke & Mayr GmbH Composition based on glycerol ether / polyol mixtures
US20110021417A1 (en) * 2003-09-19 2011-01-27 Rhoades Jonathan Robert Compositions comprising oligosaccharides
ITMO20120036A1 (en) * 2012-02-15 2013-08-16 Drex Pharma S R L ADJUSTING COMPOSITION FOR TOPICAL USE
WO2014036620A1 (en) * 2012-09-04 2014-03-13 Trassi Antonio Jose Process for manufacturing a product for treating psoriasis and product for treating psoriasis
EP2839834A1 (en) * 2013-08-19 2015-02-25 Rachid Ennamany Dermatological composition comprising plant stem cells and a derivate of salicylic acid
EP2907513A1 (en) * 2014-02-18 2015-08-19 Bionoox Suisse SA Compositions comprising dihydroquercetin for use in methods for alleviating the effects associated with skin inflammatory disorders
CN108472218A (en) * 2015-09-17 2018-08-31 尊积帕实验室有限责任公司 Composition for treating and preventing radiodermatitis and method
US11077087B2 (en) 2015-03-18 2021-08-03 Bionoox Suisse Sa Compositions comprising dihydroquercetin for use in methods for treating herpes

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20020756A1 (en) * 2002-04-09 2003-10-09 Sinclair Pharma S R L TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DERMATITIS
US20050260152A1 (en) * 2004-05-03 2005-11-24 Jaghab Khalil C Hair growth composition
TW200744658A (en) * 2005-10-12 2007-12-16 Pentapharm Ag Topical composition for use as a skin lightener
US7897800B2 (en) * 2006-02-03 2011-03-01 Jr Chem, Llc Chemical compositions and methods of making them
JP5125122B2 (en) * 2007-01-31 2013-01-23 大正製薬株式会社 Adapalene-containing external preparation composition
KR100823533B1 (en) * 2007-02-27 2008-04-30 바이오스펙트럼 주식회사 COMPOSITIONS FOR IMPROVING SKIN CONDITIONS COMPRISING alpha;-BISABOLOL AS AN ACTIVE INGREDIENT
WO2008105540A1 (en) * 2007-03-01 2008-09-04 Tk Bio-Research Laboratory Co., Ltd. Pharmaceutical agent and food effective on allergic disease and autoimmune disease
EP2155149A2 (en) * 2007-05-11 2010-02-24 Galderma Research & Development Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
CA2686556A1 (en) * 2007-05-11 2008-12-11 Galderma Research & Development Pharmaceutical or cosmetic preparations for topical and/or parenteral application, methods for the preparation thereof, and uses thereof
US20100298249A1 (en) * 2007-05-11 2010-11-25 Marc Moutet Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
US20100323985A1 (en) * 2007-05-11 2010-12-23 Marc Moutet Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
CN101496772B (en) * 2008-01-31 2013-04-24 姜宁 Anti-aging allergy-releasing composition containing plant effective ingredient
KR100823535B1 (en) * 2008-02-20 2008-04-21 바이오스펙트럼 주식회사 Compositions for Stimulating Hair Growth Comprising α-Bisabolol as an Active Ingredient
US20100249060A1 (en) * 2009-02-23 2010-09-30 Smith Jan G Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes
IT1397246B1 (en) * 2009-05-14 2013-01-04 Fidia Farmaceutici NEW MEDICATIONS FOR TOPIC USE BASED HYALURONIC ACID SULFATED AS AN ACTIVATING OR INHABITING CITHOCINIC ACTIVITY
CN103209677B (en) * 2010-10-01 2015-08-19 玫琳凯有限公司 Skin moisturizing agent and aging suppression preparaton
JP5740666B2 (en) * 2011-02-10 2015-06-24 株式会社メニコンネクト Ophthalmic composition
CN102206242A (en) * 2011-03-28 2011-10-05 中国人民解放军军事医学科学院放射与辐射医学研究所 Application of beta-glycyrrhizic acid and derivatives thereof to radiation protection
CN104010662B (en) * 2011-08-16 2016-12-21 凯诗薇有限责任公司 Make compositions and method that skin rejuvenates
WO2013047826A1 (en) * 2011-09-28 2013-04-04 ライオン株式会社 Oral composition
CN102614213A (en) * 2012-02-23 2012-08-01 武汉华纳联合药业有限公司 Application of glycyrrhizic acid, glycyrrhetinic acid or salt thereof as well as gel composition and preparation method for gel composition
WO2013141263A1 (en) * 2012-03-22 2013-09-26 富士フイルム株式会社 Highly transparent emulsion composition and highly transparent cosmetic
WO2013190548A2 (en) * 2012-06-17 2013-12-27 Kamedis Ltd Topical compositions for the treatment of chronic inflammatory skin disease
EP2705847B1 (en) * 2012-09-05 2014-07-02 PSoriasis+Creams Sweden AB Composition for treating psoriasis
US9861645B2 (en) * 2012-12-28 2018-01-09 Rak Holdings Llc Anti-itch scalp treatment compositions and combinations
CN103908458A (en) * 2013-01-04 2014-07-09 厦门鹭佳生物科技有限公司 Application of glycyrrhetinic acid and glycyrrhizic acid in preparation of medicines for preventing or treating radioactive soft tissue injury
CN103356438B (en) * 2013-07-11 2014-09-10 深圳市宜丽环保科技有限公司 Special-purposed care solution for female private part
CN103830303B (en) * 2014-03-11 2016-03-02 北京德默高科医药技术有限公司 A kind of compositions of pre-counteracting bedsores
JP6606370B2 (en) * 2015-07-30 2019-11-13 章博 田井 Antiallergic agent and mediator release inhibitor
US9949915B2 (en) 2016-06-10 2018-04-24 Clarity Cosmetics Inc. Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use
KR101839109B1 (en) * 2016-09-22 2018-03-15 ㈜프론트바이오 Composition for preventing or treating skin disease, comprising extract of purple corn
US20190321395A1 (en) * 2018-04-20 2019-10-24 Oread Therapeutics Treatment of psoriasis, seborrheic dermatitis, and eczema of the head and neck
IT201900013314A1 (en) * 2019-07-30 2021-01-30 Dermophisiologique S R L Soc Benefit Compositions for the treatment of atopic dermatitis
WO2021074718A1 (en) * 2019-10-16 2021-04-22 Tripod Maria Cream for treating acne and melasma
IT202000004069A1 (en) * 2020-02-27 2021-08-27 Ricerfarma Srl TOPICAL COMPOSITIONS FOR THE MAINTENANCE AND / OR RESTORATION OF THE INTEGRITY OF THE MUCOSA AND THE INJURED SKIN

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698360A (en) * 1985-04-09 1987-10-06 Societe Civile D'investigations Pharmacologiques D'aquitaine Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
JPH06336421A (en) * 1993-05-28 1994-12-06 Kose Corp External agent for skin
EP0694305A1 (en) * 1994-07-26 1996-01-31 INDENA S.p.A. Pharmaceutical or cosmetic formulations containing coumarins and proanthocyanidinis
DE10131641A1 (en) * 2000-12-22 2002-06-27 Schwabe Willmar Gmbh & Co St. John's wort extracts having reduced chlorophyll and proanthocyanidin contents, useful as topical medicaments, e.g. for treating stomatitis, acne, viral infections or psoriasis
EP1256335A1 (en) * 2001-05-10 2002-11-13 Cognis France S.A. Use of procyanidine oligomers

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US487774A (en) * 1892-12-13 Sectional steam-boiler
FR2509988B1 (en) * 1981-07-23 1986-05-30 Oreal MIXTURE OF VEGETABLE OILS BASED ON JOJOBA OIL AS AN OXIDATION STABILIZING AGENT AND COSMETIC COMPOSITIONS CONTAINING THE SAME
IL64700A0 (en) * 1982-01-01 1982-03-31 Binderman Itzhak Dental care compositions
JPS60109519A (en) 1983-11-17 1985-06-15 Nippon Shinyaku Co Ltd "nifedipine(r)" composition and production thereof
US5422118A (en) * 1986-11-07 1995-06-06 Pure Pac, Inc. Transdermal administration of amines with minimal irritation and high transdermal flux rate
IT1201151B (en) * 1987-01-14 1989-01-27 Indena Spa PHOSPHOLIPID COMPLEXES WITH EXTRACTS FROM VITIS VINIFERA, PROCEDURE FOR THEIR PREPARATION AND COMPOSITIONS THAT CONTAIN THEM
IT1215469B (en) 1987-05-08 1990-02-14 Yason Srl Muco-regulating and elastase inhibiting compsn.
JPH0725660B2 (en) * 1990-05-29 1995-03-22 サンスター株式会社 Cosmetics with anti-inflammatory properties against sunburn
IT1254321B (en) * 1992-04-10 1995-09-14 Kemiprogress S R L PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CUTANEOUS INFLAMMATIONS AND ORAL MUCOSA.
US5650432A (en) * 1995-03-24 1997-07-22 Jlb, Inc. Method of treating or preventing non-viral microbial infection
US5470874A (en) 1994-10-14 1995-11-28 Lerner; Sheldon Ascorbic acid and proanthocyanidine composition for topical application to human skin
US5945409A (en) * 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
JPH1059846A (en) * 1996-06-10 1998-03-03 Kikkoman Corp Preventive or remedy for cararacta
US6471972B1 (en) * 1996-11-07 2002-10-29 Lvmh Recherche Cosmetic treatment method for fighting against skin ageing effects
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
DE19880535T1 (en) * 1997-07-02 1999-04-29 Neutrogena Corp N D Ges D Staa Methods of using compositions containing dichlorophenylimidazole dioxolane to treat seborrheic dermatitis, dandruff, psoriasis and acne, and compositions thereof
EP0958833A1 (en) * 1998-05-20 1999-11-24 Erasmus Universiteit Rotterdam Methods and means for preventing or treating inflammation
IT1304183B1 (en) * 1998-12-18 2001-03-08 Indena Spa PROANTOCYANIDINE A2 COMPLEXES WITH PHOSPHOLIPIDES AS AGENTIANTIATEROSCLEROTICI.
JP2000212057A (en) * 1999-01-26 2000-08-02 Kansai Koso Kk Cosmetic composition
JP2001039844A (en) * 1999-07-29 2001-02-13 Kikkoman Corp Gargle for throat
US6274124B1 (en) * 1999-08-20 2001-08-14 Dragoco Gerberding & Co. Ag Additive for improving the water resistance of cosmetic or dermatological formulations
JP2001081021A (en) * 1999-09-09 2001-03-27 Ichimaru Pharcos Co Ltd Cosmetic composition
US6685970B1 (en) * 1999-09-21 2004-02-03 Kyowa Hakko Kogyo Co., Ltd. Compositions containing proanthocyanidin and a vitamin B6 derivative or a salt thereof
EP1226809B1 (en) * 1999-10-29 2007-05-30 Kyowa Hakko Kogyo Co., Ltd. Skin texture-improving agents
ITMI20020756A1 (en) * 2002-04-09 2003-10-09 Sinclair Pharma S R L TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DERMATITIS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698360A (en) * 1985-04-09 1987-10-06 Societe Civile D'investigations Pharmacologiques D'aquitaine Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
US4698360B1 (en) * 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
JPH06336421A (en) * 1993-05-28 1994-12-06 Kose Corp External agent for skin
EP0694305A1 (en) * 1994-07-26 1996-01-31 INDENA S.p.A. Pharmaceutical or cosmetic formulations containing coumarins and proanthocyanidinis
DE10131641A1 (en) * 2000-12-22 2002-06-27 Schwabe Willmar Gmbh & Co St. John's wort extracts having reduced chlorophyll and proanthocyanidin contents, useful as topical medicaments, e.g. for treating stomatitis, acne, viral infections or psoriasis
EP1256335A1 (en) * 2001-05-10 2002-11-13 Cognis France S.A. Use of procyanidine oligomers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EGGENSPERGER H: "ACTIVE COMPLEXES FOR SMOOTH SKIN NATURE COMBATS OXIDATIVE STRESS WIRKSTOFFKOMPLEXE FUER GLATTE HAUT NATUR GEGEN OXIDATIVEN STRESS", COSSMA: COSMETICS, SPRAY TECHNOLOGY, MARKETING, BRAUN FACHVERLAGE, KARLSRUHE, DE, vol. 2, no. 8, August 2001 (2001-08-01), pages 38 - 39, XP008016527, ISSN: 1439-7676 *
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 03 28 April 1995 (1995-04-28) *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103353A2 (en) * 2003-05-16 2004-12-02 Johnson & Johnson Consumer Companies, Inc. Topical treatment of sebum related skin conditions
WO2004103321A3 (en) * 2003-05-16 2005-02-24 Johnson & Johnson Consumer Topical treatment of ingrown hairs
WO2004103353A3 (en) * 2003-05-16 2005-02-24 Johnson & Johnson Consumer Topical treatment of sebum related skin conditions
WO2004103321A2 (en) * 2003-05-16 2004-12-02 Johnson & Johnson Consumer Companies, Inc. Topical treatment of ingrown hairs
US7252831B2 (en) 2003-05-16 2007-08-07 J&J Consumer Companies, Inc. Topical treatment of ingrown hairs
US20110021417A1 (en) * 2003-09-19 2011-01-27 Rhoades Jonathan Robert Compositions comprising oligosaccharides
WO2005037275A1 (en) * 2003-10-09 2005-04-28 Sinclair Pharmaceuticals Limited Topical compositions comprising telmesteine for treating dermatological disorders
US8431601B2 (en) 2003-10-09 2013-04-30 Sinclair Pharmaceuticals Ltd. Topical compositions comprising telmesteine for treating dermatological disorders
CN1706378B (en) * 2004-06-08 2011-04-27 味之素株式会社 Composition for treating inflammation which contains zinc pyrrolidonecarboxylate
JP2006022090A (en) * 2004-06-08 2006-01-26 Ajinomoto Co Inc Inflammation inhibitor composed of pyrrolidonecarboxylic acid zinc salt
FR2871060A1 (en) * 2004-06-08 2005-12-09 Ajinomoto Kk SUPPRESSOR AGENT FOR INFLAMMATION AND METHOD USING THE SAME
WO2008054639A3 (en) * 2006-10-30 2008-08-07 Insite Vision Inc Use of a catechin or polyphenol to treat ocular diseases and infection
WO2008054639A2 (en) * 2006-10-30 2008-05-08 Insite Vision Incorporated Use of a catechin or polyphenol to treat ocular diseases and infection
DE102007017851A1 (en) * 2007-04-16 2008-10-23 Schülke & Mayr GmbH Composition based on glycerol ether / polyol mixtures
US8058218B2 (en) 2007-04-16 2011-11-15 Air Liquide Sante (International) Composition based on glycerol ether/polyol mixtures
US8093193B2 (en) 2007-04-16 2012-01-10 Air Liquide Sante (International) Composition based on glycerol ether/polyol mixtures
EP2628487A1 (en) * 2012-02-15 2013-08-21 Drex Pharma S.R.L. Adjuvant composition for topical use
ITMO20120036A1 (en) * 2012-02-15 2013-08-16 Drex Pharma S R L ADJUSTING COMPOSITION FOR TOPICAL USE
WO2014036620A1 (en) * 2012-09-04 2014-03-13 Trassi Antonio Jose Process for manufacturing a product for treating psoriasis and product for treating psoriasis
EP2839834A1 (en) * 2013-08-19 2015-02-25 Rachid Ennamany Dermatological composition comprising plant stem cells and a derivate of salicylic acid
EP2907513A1 (en) * 2014-02-18 2015-08-19 Bionoox Suisse SA Compositions comprising dihydroquercetin for use in methods for alleviating the effects associated with skin inflammatory disorders
WO2015124644A1 (en) * 2014-02-18 2015-08-27 Bionoox Suisse Sa Compositions comprising dihydroquercetin for use in methods for treating the effects associated with skin inflammatory disorders
US9956200B2 (en) 2014-02-18 2018-05-01 Bionoox Suisse Sa Compositions comprising dihydroquercetin for use in methods for treating the effects associated with skin inflammatory disorders
US11077087B2 (en) 2015-03-18 2021-08-03 Bionoox Suisse Sa Compositions comprising dihydroquercetin for use in methods for treating herpes
CN108472218A (en) * 2015-09-17 2018-08-31 尊积帕实验室有限责任公司 Composition for treating and preventing radiodermatitis and method
EP3349719A4 (en) * 2015-09-17 2019-05-22 June Jacobs Laboratories, Llc Compositions and methods for the treatment and prevention of radiation dermatitis

Also Published As

Publication number Publication date
PL204953B1 (en) 2010-02-26
NZ535813A (en) 2007-09-28
BR0309061A (en) 2005-02-01
HK1075617A1 (en) 2005-12-23
TW200306849A (en) 2003-12-01
ATE361084T1 (en) 2007-05-15
IL164434A0 (en) 2005-12-18
KR101065645B1 (en) 2011-09-20
TWI345979B (en) 2011-08-01
DK1494692T3 (en) 2007-09-17
RU2004129727A (en) 2005-06-10
RU2320362C2 (en) 2008-03-27
JP2005526822A (en) 2005-09-08
AU2003226754B2 (en) 2007-08-16
PT1494692E (en) 2007-05-31
CN1646151A (en) 2005-07-27
PL371853A1 (en) 2005-06-27
US20050143324A1 (en) 2005-06-30
ITMI20020756A0 (en) 2002-04-09
AR039269A1 (en) 2005-02-16
EP1494692B1 (en) 2007-05-02
IL164434A (en) 2009-09-22
KR20040104561A (en) 2004-12-10
CN1646151B (en) 2010-05-05
ITMI20020756A1 (en) 2003-10-09
BRPI0309061B1 (en) 2017-09-12
HRP20040917B1 (en) 2013-03-31
ES2285158T3 (en) 2007-11-16
ZA200408100B (en) 2006-07-26
AU2003226754A1 (en) 2003-10-20
US20060247183A1 (en) 2006-11-02
CA2481770A1 (en) 2003-10-16
CA2481770C (en) 2011-10-04
JO2448B1 (en) 2008-10-09
NO332753B1 (en) 2013-01-07
MXPA04009755A (en) 2004-12-13
US20080015155A1 (en) 2008-01-17
GEP20074176B (en) 2007-08-10
HRP20040917A2 (en) 2005-02-28
NO20044259L (en) 2005-01-06
DE60313597D1 (en) 2007-06-14
US20080114057A1 (en) 2008-05-15
US7262180B2 (en) 2007-08-28
CY1106628T1 (en) 2012-01-25
DE60313597T2 (en) 2007-09-06
EP1494692A1 (en) 2005-01-12
UA81408C2 (en) 2008-01-10
MY137060A (en) 2008-12-31
JP4861606B2 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
EP1494692B1 (en) Topical pharmaceutical compositions comprising proanthocyanidins, glycyrrhetinic acid and telmesteine for the treatment of dermatitis
JP2002512971A (en) Topical substance mixture containing olive oil and honey
US20080045594A1 (en) Use of at Least One Conjugated Triene-Containing Fatty Acid for Preparing a Medicine for Treating Inflammation
DE202005007603U1 (en) Composition for oral or topical administration, e.g. as a dietary supplement or dietetic food, shower gel, body lotion, cream or care concentrate, comprises argan oil and nigella oil
WO2004062637A1 (en) Cosmetic composition comprising a metalloproteinase inhibitor and a lipopeptide
US20040214750A1 (en) Medicaments for healing skin conditions in humans
US6303651B1 (en) Synergistic antioxidant veterinary compositions
WO2001019365A1 (en) Pharmaceutical and/or cosmetical compositions
JPH08245409A (en) Skin preparation for external use and bathing agent
KR101418366B1 (en) Composition containing bee venom and propolis for preventing or treating acne
WO2015057110A2 (en) Cosmetic for rapid skin regeneration
KR102359285B1 (en) Composition of at least one protease inhibitor and at least one active ingredient for use in the prevention and/or treatment of skin lesions
KR20050072378A (en) Compositions of cosmetics for atopy skin containing specific oriental herbal extracts
RU2501560C1 (en) Composition containing enzyme ribonuclease and/or stearyl glycyrrhetinate or glycyrrhetinic acid or salt thereof: ammonium or dipotassium or trisodium glycyrrhizinate
WO2023218391A1 (en) Extracts in eutectic solvent of olive oil polyphenols, compositions, uses and methods of preparation thereof
KR20040033945A (en) Materials containing Soap aloe(African aloe) of cosmatics made for a pimpled face
HU209867B (en) Cosmetic composition and process for making medicative composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1-2004-501552

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 3006/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: P20040917A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/009755

Country of ref document: MX

Ref document number: 2003745775

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004/08100

Country of ref document: ZA

Ref document number: 8438

Country of ref document: GE

Ref document number: 1020047015962

Country of ref document: KR

Ref document number: 535813

Country of ref document: NZ

Ref document number: 2003226754

Country of ref document: AU

Ref document number: 2481770

Country of ref document: CA

Ref document number: 2003581793

Country of ref document: JP

Ref document number: 200408100

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 20038078589

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 10963848

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2004129727

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020047015962

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003745775

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003745775

Country of ref document: EP